H.C. Wainwright raised the firm’s price target on Alto Neuroscience (ANRO) to $50 from $10 and keeps a Buy rating on the shares. The firm incorporated the potential value from ALTO-207 in treatment-resistant depression into the company’s model. The target increase reflects ALTO-207’s blockbuster potential in TRD along with Alto’s announced financing and “clear” regulatory path, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANRO:
- Alto Neuroscience price target raised to $16 from $10 at Baird
- Alto Neuroscience Secures $50M in Private Placement
- Alto Neuroscience, Inc.: Accelerated Drug Development and Strong Clinical Trial Compliance Drive Buy Rating
- Midday Fly By: AWS hit by outage, Kering sells beauty unit
- Alto Neuroscience, Inc.: Strategic Advancements and Financial Strength Drive Buy Rating